Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its financial
results for the three and twelve month periods ending December 31, 2016
on Wednesday March 8, 2017 before the market opens and host a conference
call on Wednesday, March 8, 2017 at 8:30 a.m. Eastern Time.
To access the call live, please dial 416-340-2216 or 1-866-225-2055.
Listeners are encouraged to dial in 10 minutes before the call begins to
avoid delays. A replay of the conference call will be available until
11:59 p.m. Eastern Time on Thursday, March 16, 2017 by dialing
905-694-9451 or 1-800-408-3053, using access code: 1212516#.
Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company
focused on the development, manufacture, marketing and distribution of
innovative, branded products that improve the patient experience.
Acerus currently markets two products in Canada: ESTRACE®, a
product indicated for the symptomatic relief of menopausal symptoms; and
NATESTO®, the first and only testosterone nasal gel for
testosterone replacement therapy in adult males diagnosed with
hypogonadism. Acerus’ pipeline includes two new innovative products:
GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic,
used in the treatment of atrophic vaginitis, restoration of vaginal
flora and treatment of certain vaginal infections; and TEFINA™, a ‘use
as required’ drug development candidate, aimed at addressing a
significant unmet need for women with female sexual dysfunction.
For more information, visit www.aceruspharma.com
and follow us on Twitter
View source version on businesswire.com: http://www.businesswire.com/news/home/20170228006534/en/
Source: Acerus Pharmaceuticals Corporation